CD38 is a transmembrane glycoprotein expressed on the surface of different cell
lines with several functions (receptor, adhesion molecule, ectoenzyme). Based on
its high expression in multiple myeloma cells, CD38 is one of the main molecules
used in the target therapy age. Daratumumab is the first fully human monoclonal
antibody tested in clinical trials, showing efficacy in relapsed/refractory multiple
myeloma patients, especially in combination with immunomodulants and/or proteasome
inhibitors. The synergic effect concerns multiple myeloma cells as well as
the microenvironment (NK cells, macrophage, regulatory B/T cells and CD8+ effector
cells). Therefore, the anti-multiple myeloma activity of Daratumumab greatly
depends on the immune system: this is the reason why several ongoing clinical trial
are testing its efficacy in the naïve patients, with a more effective immune system
